Jessica Leung1, Claire Owen2, David Liew3 and Russell Buchanan3, 1Austin Health, Preston, Victoria, Australia, 2Austin Health, Malvern East, Australia, 3Austin Health, Heidelberg, Australia
Background/Purpose: Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients of additional symptoms including fatigue and sleep disturbance. These features of PMR are less recognised by clinicians and have not yet been quantified in the literature. Furthermore, the adequacy of the current treatment paradigm in addressing these symptoms is unknown.
Methods: Patients with a new diagnosis of PMR fulfilling 2012 EULAR/ACR Provisional Classification Criteria were prospectively recruited, together with age- and gender-matched controls. Assessments were undertaken three months after the commencement of corticosteroid therapy, when it was considered likely that inflammatory disease would be controlled.
PMR disease activity was assessed using the PMR-Activity Score (PMR-AS). Patient-reported outcomes were used to assess fatigue (BRAF-MDQ), sleep (PSQI), anxiety and depression (HADS). The two-sample t-test and Mann-Whitney U test were conducted to compare scores in PMR participants versus control participants.
Results: Over the period April 2019 to August 2021, 36 participants with PMR and 32 control participants were recruited. The mean age of PMR participants was 68.7 (SD 8.3) years and 18 (50%) were females. The mean duration of steroid therapy prior to study assessments was 12.8 (SD 2.1) weeks. Disease activity at the time of assessments was low (median PMR-AS 4.1; IQR 1.7, 10.2).
PMR participants had a higher PSQI score compared to control participants, indicating lower quality sleep (mean 8.8 [SD 4.5] vs 5.3 [SD 2.9], difference 3.6 [95% CI 1.8 - 5.4], p< 0.001). The median BRAF score in PMR participants was higher than in control participants (22 [IQR 2, 32.5] vs 6 [IQR 2, 14.5], p=0.004). Median HAD depression and HAD anxiety scores were also higher in PMR participants (3 [IQR 2, 7] vs 1 [IQR 0, 3], p< 0.001; and 5 [IQR 3, 8] vs 2 [IQR 0, 3.5], p< 0.001 respectively).
Conclusion: Despite treatment-induced low disease activity at the time of assessment, PMR participants had significantly higher levels of fatigue, anxiety, depression and poorer quality of sleep compared to control participants. These results support previous insights from qualitative studies and underscore shortfalls of the current treatment approach based on corticosteroid monotherapy. Future research should explore risk factors and both pharmacological and non-pharmacological management strategies.
Disclosures: J. Leung, Novartis, Fresenius Kabi, Eli Lilly, AbbVie; C. Owen, None; D. Liew, None; R. Buchanan, None.
